AI illustration · not actual product photoDetails from the source.
This catalogue entry records MGF, 2 mg × 10 vials (SKU FM2), using the supplied source listing. The cited dossier describes: Laboratory and animal research examines IGF-1Ec/MGF responses to mechanical loading or injury, muscle precursor-cell activity and repair, and experimental bone, cartilage, and neural-injury contexts. These are research areas, not established uses of the exact catalogue item. It also distinguishes available human evidence, limitations, safety concerns, and regulatory context. It does not verify this supplier-specific item’s identity, formulation, lot quality, or approval. This is not medical advice, a treatment recommendation, or authorization for human use.
- Catalogue code
- FM2
- Source specification
- 2mg*10vials
- Source document
- PriceList(1).pdf, page 2
- Photograph
- AI-generated illustration only — not an actual product photo or verified molecular depiction; owner-approved product photo still pending.
Product information is presented from supplied source materials. Inclusion on this website does not state that a product is an approved medicine or authorize human use. This is educational content, not medical advice.
Compound-level research and safety context.
Evidence below concerns the research family associated with this listing. For blends, findings about individual components do not establish evidence for the combination. This does not verify the supplier-specific vial or lot. Reviewed 2026-10-30.
What it is
The exact catalogue label is MGF (source SKU FM2), listed as *10vials at 36 per 10 vials; the price list states no currency. In scientific usage, MGF can mean the IGF-1Ec splice isoform or a synthetic E-domain fragment, often MGF-24aa. Those are peptides/protein-derived entities, but the label and supplied documentation do not identify which, if either, is in this exact vial. No inference about the vial's sequence, PEGylation, formulation, or manufacturing status is justified.
Biological mechanism
Human IGF-1Ec is an alternatively spliced IGF-1 form with a distinct E-domain region. MGF also names synthetic E-domain peptides in some research papers. Suggested cellular effects include increasing muscle precursor-cell proliferation and delaying differentiation, but endogenous E-domain processing and the standalone peptide's mechanism remain uncertain. Evidence does not identify the mechanism of FM2.
Research focus
Laboratory and animal research examines IGF-1Ec/MGF responses to mechanical loading or injury, muscle precursor-cell activity and repair, and experimental bone, cartilage, and neural-injury contexts. These are research areas, not established uses of the exact catalogue item.
Potential applications in the evidence
Potential areas investigated include muscle-cell repair and maintenance, muscle precursor-cell transplantation, and preclinical bone, cartilage, and neural injury models. Such potential applications are investigational hypotheses, not demonstrated human treatments or claims about FM2.
Human evidence
Human studies have measured MGF-related muscle mRNA after exercise; one small study found an increase after resistance exercise in younger but not older participants. That is an endogenous gene-expression observation, not administration of MGF. Another study tested a defined synthetic 24-amino-acid MGF E-peptide on cultured human muscle precursor cells; it was not a clinical trial in people. The evidence reviewed does not establish clinical benefit or safety from administering synthetic MGF, and does not identify the substance in FM2.
Known and potential effects
No reliable adverse-effect profile has been established for the exact FM2 item. Cell-level research reports effects on muscle precursor-cell proliferation and differentiation under laboratory conditions; these are not proven clinical effects. The FDA reports potential immunogenicity, peptide-related impurity, and API-characterization concerns for compounded PEG-MGF in certain contexts, but that notice concerns PEG-MGF specifically and does not establish that FM2 is PEGylated or compounded. Adverse effects listed for mecasermin apply to that distinct, FDA-approved full-length IGF-1 product, not automatically to MGF or FM2.
Safety and contraindications
The exact active ingredient, sequence, formulation, manufacturer, lot, quality, and intended jurisdiction are not provided, so product-specific hazards and contraindications cannot be verified. The FDA's PEG-MGF compounding safety discussion is relevant only if the item is established to be PEG-MGF and should not be silently applied to this listing. Mecasermin's contraindications and warnings cannot be transferred to the catalogue vial. No safety guarantee or specific contraindication profile is supported for FM2.
U.S. FDA / regulatory status
The FDA-approved medicine INCRELEX is recombinant full-length human IGF-1 (mecasermin) for a specified pediatric growth-failure indication; its approval does not transfer to MGF/IGF-1Ec or to the exact FM2 vial. The FDA compounding safety page discusses PEG-MGF specifically, not a general FDA approval of MGF. No FDA approval for a product matching FM2 was verified in the sources reviewed. The supplied documents do not identify manufacturer, lot, formulation source, jurisdiction, or approval documentation. Do not label the exact item FDA-approved, compounded, or research-only without reliable supporting documentation.
Evidence limitations
The term MGF is used inconsistently for an IGF-1 splice isoform and for synthetic E-domain peptides. Most evidence is mechanistic, cell-based, or animal research. Human findings reviewed concern endogenous transcript expression or isolated human cells, not clinical administration. FDA information for PEG-MGF and mecasermin is specific to those products and cannot establish the identity, safety, or regulatory status of FM2.
Supporting sources
- Expression of IGF-I splice variants in young and old human skeletal muscle after high resistance exercise The Journal of Physiology; PubMed Central · Primary human exercise study. Supports: Human MGF transcript response after exercise and the distinction between observing endogenous mRNA and administering an MGF product.
- Mechano Growth Factor E peptide (MGF-E), derived from an isoform of IGF-1, activates human muscle progenitor cells and induces an increase in their fusion potential at different ages Mechanisms of Ageing and Development; Elsevier · Primary in-vitro study using human muscle cells. Supports: Experiments with a defined synthetic 24-amino-acid E-peptide on cultured human muscle progenitor cells; does not establish clinical treatment effects.
- Mechano-Growth Factor: an important cog or a loose screw in the repair machinery? Frontiers in Endocrinology · Peer-reviewed review. Supports: IGF-1 splice-variant and E-domain terminology, proposed mechanisms, evidence gaps, and preclinical-versus-human limitations.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks U.S. Food and Drug Administration · Official regulator compounding-safety page. Supports: FDA's specific risk statement about PEG-MGF in compounded drugs and the stated limits of what FDA reports about human exposure; does not establish this catalogue item's identity or status.
- INCRELEX (mecasermin) injection, for subcutaneous use: Prescribing Information U.S. Food and Drug Administration · Official FDA-approved product label. Supports: Identity and specific indication of FDA-approved full-length mecasermin and its product-specific warnings; used to distinguish it from MGF and FM2.